Idience Targeted Cancer Drug Candidate ‘Venadaparib’ Granted FDA Fast Track Designation
Idience, a novel anticancer drug developer under the Ildong Pharmaceutical Group, announced on the 18th that its targeted cancer drug candidate...
Search results for "new drug development"
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?
Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous injections to subcutaneous...
Why Rokit Healthcare’s Stock Soared Despite Geopolitical Volatility
Rokit Healthcare is capturing significant market attention for its robust momentum. Its stock price has surged 50% over...
Datroway Approved: New Targeted Therapy Offers Hope for Metastatic Breast Cancer
A new therapeutic horizon has arrived for patients battling metastatic breast cancer that has progressed despite...
Korean Biotech Firms Join Forces to Uncover the Hidden Profiles of Cancer Cells
Even within a single tumor, cancer cells present many different "faces." While they may appear as a uniform mass, every...
Decoding the Blueprint of Aging: Scientists Map 7 Million Cells Across 21 Organs
We often attribute the appearance of wrinkles, declining stamina, and increased disease risk simply to "getting older.
Beyond the X-Ray: South Korean Researchers Develop AI to Pinpoint Precise Knee Osteoarthritis Wear
A South Korean research team has developed a breakthrough imaging indicator that utilizes AI deep learning to identify...
Alteogen Poised for Surge in Milestone Revenue as Keytruda Qlex and Biosimilars Gain Momentum
Alteogen is set to accelerate its financial growth this year, driven by a surge in milestone payments and royalty...
FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate
Abl Bio announced on March 3rd that the U.S. Food and Drug Administration has approved the Investigational New Drug...
VigenCell "Primary Endpoint Achieved"... Will a Domestic NK/T Lymphoma New Drug Be Born?
VigenCell has announced plans to apply for conditional approval within the year as it successfully completed...